
    
      This is a 1-month, prospective, multicenter, randomized, dose-ranging, sham-controlled,
      blinded study in which eligible subjects with either unilateral or bilateral acute otitis
      media with tympanostomy tubes (AOMT) will receive a single administration of 6 mg OTO-201, 12
      mg OTO-201, or sham into the affected ear(s).
    
  